Acquisition by Randolph Sophia of 123000 shares of Alx Oncology subject to Rule 16b-3

ALXO Stock  USD 1.62  0.14  9.46%   
About 52% of Alx Oncology's investor base is interested to short. The analysis of the overall investor sentiment regarding Alx Oncology Holdings suggests that many traders are impartial. Alx Oncology's investing sentiment overview a quick insight into current market opportunities from investing in Alx Oncology Holdings. Many technical investors use Alx Oncology Holdings stock news signals to limit their universe of possible portfolio assets and to time the market correctly.
  
Filed transaction by Alx Oncology Holdings Officer Chief Medical Officer. Grant, award or other acquisition pursuant to Rule 16b-3

Read at macroaxis.com
Alx insider trading alert for acquisition of employee stock option (right to buy) by Randolph Sophia, Officer: Chief Medical Officer, on 8th of April 2024. This event was filed by Alx Oncology Holdings with SEC on 2022-08-05. Statement of changes in beneficial ownership - SEC Form 4

Cash Flow Correlation

Alx Oncology's cash-flow correlation analysis can be used to evaluate the unsystematic risk during the given period. It also helps investors identify the Alx Oncology's relationships between the major components of the statement of changes in financial position and other commonly used cash-related accounts. When such correlations are discovered, they may help managers and analysts to enhance performance or determine appealing investment opportunities.
Click cells to compare fundamentals

Alx Oncology Investor Sentiment by Other News Outlets

Investor sentiment, mood or attitude towards Alx Oncology can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.

Alx Oncology Fundamental Analysis

We analyze Alx Oncology's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Alx Oncology using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Alx Oncology based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Working Capital

Working Capital Comparative Analysis

Alx Oncology is currently under evaluation in working capital category among its peers. Working Capital is a measure of company efficiency and operating liquidity. The working capital is usually calculated by subtracting Current Liabilities from Current Assets. It is an important indicator of the firm ability to continue its normal operations without additional debt obligations. .

Alx Oncology Holdings Potential Pair-trading

One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Alx Oncology stock to make a market-neutral strategy. Peer analysis of Alx Oncology could also be used in its relative valuation, which is a method of valuing Alx Oncology by comparing valuation metrics with similar companies.

Peers

Alx Oncology Related Equities

IPSCCentury Therapeutics   4.76   
0%
41.0%
MLYSMineralys Therapeutics,   4.31   
0%
37.0%
CCCCC4 Therapeutics   2.78   
0%
23.0%
CGEMCullinan Oncology   2.33   
0%
20.0%
RVMDRevolution Medicines   1.78   
0%
15.0%
CRNXCrinetics Pharmaceuticals   1.63   
0%
14.0%
AVTEAerovate Therapeutics   1.19   
0%
10.0%
EWTXEdgewise Therapeutics   0.06   
1.0%
0%
EYPTEyepoint Pharmaceuticals   0.28   
2.0%
0%
IMTXImmatics   0.44   
3.0%
0%
STOKStoke Therapeutics   0.60   
5.0%
0%
CABACabaletta Bio   0.84   
7.0%
0%
DYNDyne Therapeutics   1.28   
11.0%
0%
BDTXBlack Diamond   1.35   
11.0%
0%
PASGPassage Bio   1.52   
13.0%
0%
VIRXViracta Therapeutics   4.55   
39.0%
0%
BMEABiomea Fusion   4.73   
40.0%
0%
BCABBioatla   11.59   
100.0%
0%
When determining whether Alx Oncology Holdings offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Alx Oncology's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Alx Oncology Holdings Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Alx Oncology Holdings Stock:
Check out Alx Oncology Hype Analysis, Alx Oncology Correlation and Alx Oncology Performance.
You can also try the Price Exposure Probability module to analyze equity upside and downside potential for a given time horizon across multiple markets.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Alx Oncology. If investors know Alx will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Alx Oncology listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(2.97)
Quarterly Revenue Growth
(1.00)
Return On Assets
(0.49)
Return On Equity
(0.99)
The market value of Alx Oncology Holdings is measured differently than its book value, which is the value of Alx that is recorded on the company's balance sheet. Investors also form their own opinion of Alx Oncology's value that differs from its market value or its book value, called intrinsic value, which is Alx Oncology's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Alx Oncology's market value can be influenced by many factors that don't directly affect Alx Oncology's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Alx Oncology's value and its price as these two are different measures arrived at by different means. Investors typically determine if Alx Oncology is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Alx Oncology's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.